Oruka Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Oruka Therapeutics, Inc. (ORKA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $25.00 thousand for the 6-month period ending 2024-06-30, per its 10-Q filed 2024-08-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2024-08-01
- Oruka Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-06-30 was $9.00K, a 64.00% decline year-over-year.
- Oruka Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2024-03-31 was $16.00K, a 36.00% decline year-over-year.
- Oruka Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-12-31 was $20.00K, a 16.67% decline year-over-year.
- Oruka Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2023-09-30 was $26.00K, a 8.33% increase year-over-year.
- Oruka Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $96.00K, a 2.13% increase from fiscal 2022.
- Oruka Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $94.00K, a 25.33% increase from fiscal 2021.
- Oruka Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $75.00K, a 11.76% decline from fiscal 2020.
- Oruka Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $85.00K, a 19.72% increase from fiscal 2019.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $9.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $25.00K 10-Q · filed 2024-08-01 | $45.00K derived: sum of 3 quarters · filed 2024-08-01 | $71.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | $16.00K 10-Q · filed 2024-04-25 | $36.00K derived: sum of 2 quarters · filed 2024-04-25 | $62.00K derived: sum of 3 quarters · filed 2024-04-25 | $87.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-01 | $46.00K derived: sum of 2 quarters · filed 2024-02-01 | $71.00K derived: sum of 3 quarters · filed 2024-08-01 | $96.00K 10-K · filed 2024-02-01 |
| 2023-09-30 | $26.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-18 | $51.00K derived: sum of 2 quarters · filed 2024-08-01 | $76.00K 10-Q · filed 2023-10-18 | $100.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $50.00K 10-Q · filed 2024-08-01 | $74.00K derived: sum of 3 quarters · filed 2024-08-01 | $98.00K derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | $25.00K 10-Q · filed 2024-04-25 | $49.00K derived: sum of 2 quarters · filed 2024-04-25 | $73.00K derived: sum of 3 quarters · filed 2024-04-25 | $96.00K derived: sum of 4 quarters · filed 2024-04-25 |
| 2022-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-01 | $48.00K derived: sum of 2 quarters · filed 2024-02-01 | $71.00K derived: sum of 3 quarters · filed 2024-02-01 | $94.00K 10-K · filed 2024-02-01 |
| 2022-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-18 | $47.00K derived: sum of 2 quarters · filed 2023-10-18 | $70.00K 10-Q · filed 2023-10-18 | $93.00K derived: sum of 4 quarters · filed 2023-10-18 |
| 2022-06-30 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-21 | $46.00K 10-Q · filed 2023-07-21 | $69.00K derived: sum of 3 quarters · filed 2023-07-21 | $91.00K derived: sum of 4 quarters · filed 2023-07-21 |
| 2022-03-31 | $23.00K 10-Q · filed 2023-04-24 | $46.00K derived: sum of 2 quarters · filed 2023-04-24 | $68.00K derived: sum of 3 quarters · filed 2023-04-24 | $84.00K derived: sum of 4 quarters · filed 2023-04-24 |
| 2021-12-31 | $23.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $45.00K derived: sum of 2 quarters · filed 2023-02-24 | $61.00K derived: sum of 3 quarters · filed 2023-02-24 | $75.00K 10-K · filed 2023-02-24 |
| 2021-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $38.00K derived: sum of 2 quarters · filed 2022-10-28 | $52.00K 10-Q · filed 2022-10-28 | $66.00K derived: sum of 4 quarters · filed 2022-10-28 |
| 2021-06-30 | $16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $30.00K 10-Q · filed 2022-08-02 | $44.00K derived: sum of 3 quarters · filed 2022-08-02 | $68.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $14.00K 10-Q · filed 2022-05-02 | $28.00K derived: sum of 2 quarters · filed 2022-05-02 | $52.00K derived: sum of 3 quarters · filed 2022-05-02 | $77.00K derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | $14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $38.00K derived: sum of 2 quarters · filed 2022-03-14 | $63.00K derived: sum of 3 quarters · filed 2022-03-14 | $85.00K 10-K · filed 2022-03-14 |
| 2020-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $49.00K derived: sum of 2 quarters · filed 2021-11-02 | $71.00K 10-Q · filed 2021-11-02 | $93.00K derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $47.00K 10-Q · filed 2021-08-04 | $69.00K derived: sum of 3 quarters · filed 2021-08-04 | $86.00K derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-03-31 | $22.00K 10-Q · filed 2021-05-11 | $44.00K derived: sum of 2 quarters · filed 2021-05-11 | $61.00K derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $39.00K derived: sum of 2 quarters · filed 2021-03-18 | $71.00K 10-K · filed 2021-03-18 | |
| 2019-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $49.00K 10-Q · filed 2020-11-02 | ||
| 2019-06-30 | $32.00K 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |